Back to top
more

Hologic (HOLX)

(Delayed Data from NSDQ)

$67.81 USD

67.81
4,294,477

-0.25 (-0.37%)

Updated Aug 15, 2025 04:00 PM ET

After-Market: $67.84 +0.03 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 38% (152 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Here's Why You Should Add Abbott (ABT) to Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Abbott (ABT) due to a slew of product launches and regulatory approvals.

Zacks Equity Research

Orthofix's (OFIX) Q4 Earnings Top Estimates, Margin Declines

by Zacks Equity Research

Orthofix (OFIX) registers improvement in Global Spine segment's revenues during Q4 due to strength in its spinal implants portfolio.

Zacks Equity Research

Teleflex (TFX) Beats on Q4 Earnings and Revenues, Margins Fall

by Zacks Equity Research

Teleflex (TFX) witnesses significant sequential improvement in segmental performance during the fourth quarter on gradual recovery of the economy.

Zacks Equity Research

Glaukos (GKOS) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Glaukos' (GKOS) fourth-quarter results reflect rise in revenues and recovery in the U.S. Glaucoma franchise.

Zacks Equity Research

LHC Group (LHCG) Q4 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

LHC Group's (LHCG) fourth-quarter results benefit from organic growth in home health and hospice admissions.

Zacks Equity Research

NuVasive's (NUVA) Q4 Earnings Top Estimates, Margin Declines

by Zacks Equity Research

NuVasive (NUVA) registers strong international performance in Q4 along with continued adoption of advanced material science implants in the U.S. Spinal Hardware business.

Zacks Equity Research

Tandem Diabetes' (TNDM) Q4 Earnings, Revenues Top Estimates

by Zacks Equity Research

Tandem Diabetes' (TNDM) strong domestic and international pump sales and shipments boosted the Q4 top line.

Zacks Equity Research

Inogen (INGN) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Inogen's (INGN) fourth-quarter results benefit from higher rental revenues and strength in business-to-business revenues.

Zacks Equity Research

Nevro (NVRO) Q4 Loss Narrower Than Estimated, Revenues Miss

by Zacks Equity Research

Nevro's (NVRO) domestic and international revenues fell on a year-over-year basis in the fourth quarter.

Zacks Equity Research

Merit Medical (MMSI) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Merit Medical (MMSI) benefits from growth in revenues at the Cardiovascular segment in Q4.

Zacks Equity Research

Masimo (MASI) Earnings and Revenues Beat Estimates in Q4

by Zacks Equity Research

Masimo (MASI) continues to gain from its key Product segment, which witnessed solid growth in Q4.

Zacks Equity Research

Here's Why You Should Retain Avanos Medical (AVNS) Stock Now

by Zacks Equity Research

Investor confidence is high in Avanos Medical (AVNS) stock, courtesy of its solid prospects.

Zacks Equity Research

Myriad Genetics (MYGN) Beats on Q2 Revenues, Earnings in Line

by Zacks Equity Research

Myriad Genetics' (MYGN) sales in majority of the operating segments improved in the quarter despite pandemic-led business challenges.

Zacks Equity Research

Insulet (PODD) Q4 Earnings Fall Shy of Estimates, Revenues Beat

by Zacks Equity Research

Insulet's (PODD) Q4 revenues were significantly boosted by the robust adoption of Omnipod DASH and a growing customer base.

Zacks Equity Research

Fresenius Medical (FMS) Q4 Earnings Beat, Revenues Miss

by Zacks Equity Research

Fresenius Medical's (FMS) fourth-quarter earnings benefit from strength in Health Care Products segment, and performance across EMEA and Asia Pacific.

Zacks Equity Research

Medtronic's (MDT) Q3 Earnings Beat Estimates, Margins Fall

by Zacks Equity Research

Medtronic (MDT) procedure volumes hurt by resurgence of COVID-19 cases despite increased demand for related diagnostics and therapies.

Zacks Equity Research

Integer Holdings (ITGR) Gains 2.4% Post Q4 Earnings Beat

by Zacks Equity Research

Integer Holdings' (ITGR) fourth-quarter results reflect weak segmental performance.

Zacks Equity Research

Pacific Biosciences' (PACB) Sequel II Gets Deployed by LabCorp

by Zacks Equity Research

Pacific Biosciences' (PACB) Sequel II HiFi sequencing gets utilized by LabCorp to detect SARS-COV-2 variants in the United States.

Zacks Equity Research

BD (BDX), Scanwell Health Collaborate on At-Home Coronavirus Test

by Zacks Equity Research

BD (BDX) plans to develop a lateral flow antigen test and pair it with the Scanwell Health mobile app via the latest partnership.

Zacks Equity Research

Here's Why You Should Retain DaVita (DVA) in Your Portfolio Now

by Zacks Equity Research

Investors' confidence is high on the DaVita (DVA) stock, thanks to solid prospects.

Urmimala Biswas headshot

4 Medical Products Stocks Set to Beat This Earnings Season

by Urmimala Biswas

Rebound in sales volumes and rise in COVID-19 support products sales make us optimistic about MDT, MASI, XRAY and COO's results.

Zacks Equity Research

Here's Why You Should Add Hologic (HOLX) to Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Hologic (HOLX) due to a slew of product launches.

Zacks Equity Research

Avanos Medical (AVNS) Q4 Earnings and Revenues Top Estimates

by Zacks Equity Research

Avanos Medical (AVNS) continues to gain from its core Chronic Care segment in the fourth quarter.

Zacks Equity Research

AMN Healthcare (AMN) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

AMN Healthcare (AMN) gains from the Nurse and Allied Solutions segment in the fourth quarter.

Zacks Equity Research

Syneos Health (SYNH) Posts In-Line Q4 Earnings, Margins Up

by Zacks Equity Research

Syneos Health (SYNH) registers sales decline in both its business segments due to slower recovery in reimbursable out-of-pocket expenses across both segments.